ONCOFoCUS ikon

1.6 by Portable Medical Technology Ltd.


Mar 3, 2019

Mengenai ONCOFoCUS

Malaysia

Aplikasi FN menilai jika pesakit yang berisiko untuk neutropenia demam.

ONCOFoCUS Febrile Neutropenia Risk Assessment. The application allows you to assess if a patient undergoing chemotherapy is at risk of febrile neutropenia. Through a series of standardised questions based on EORTC and NCCN guidelines, the tool asks you to consider the numerous factors that may contribute to an increased risk.

Benefits

· It allows you to reference the EORTC and NCCN estimated risk associated with Febrile Neutropenia across all of the major chemotherapy regimes.

·All of the content is accessible via your mobile device, this means you can access the content “on the go”, to allow for fast, efficient decision making.

- The results of your assessments can be shared with colleagues via PDF and saved within the history section of the application. This facilitates collaboration with your colleagues.

ONCOFoCUS This tool is offered to you as a part of Teva's OncoFocus initiative. OncoFocus (Zoom on people) is our commitment to support the patient and the Healthcare professional across the continuum of care throughout the patient journey.

Apa yang baru dalam versi terkini 1.6

Last updated on Mar 3, 2019

Text changes for the Australian market.

Terjemahan Memuatkan...

Maklumat APLIKASI tambahan

Versi Terbaru

Minta ONCOFoCUS Kemas kini 1.6

Dimuat naik oleh

Nurlina Afriany

Memerlukan Android

Android 4.0+

Available on

Dapatkan ONCOFoCUS melalui Google Play

Tunjukkan Lagi

ONCOFoCUS Tangkapan skrin

Memuatkan Komen...
Bahasa
Bahasa
Mencari...
Langgan APKPure
Jadilah yang pertama untuk mendapatkan akses kepada pelepasan awal, berita, dan panduan permainan dan aplikasi Android terbaik.
Tidak, Terima kasih
Daftar
Berjaya berjaya!
Anda kini melanggan APKPure.
Langgan APKPure
Jadilah yang pertama untuk mendapatkan akses kepada pelepasan awal, berita, dan panduan permainan dan aplikasi Android terbaik.
Tidak, Terima kasih
Daftar
Kejayaan!
Anda kini melanggan surat berita kami.